AGS-62P1

N/A

Report date: 2024/02/05 13:52:47

Base Information

Drug NameAGS-62P1

Drug Alias NameAGS62P1ASP-1235

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors

TargetsTyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAmbrx Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAstellas Pharma Global Development Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A